Cargando…
54. tGLI1 IS AN ACTIONABLE THERAPEUTIC TARGET IN BREAST CANCER BRAIN METASTASES
Breast cancer is the second leading cause of brain metastases in women; patients with breast cancer brain metastasis (BCBM) survive an average of 6–18 months following diagnosis. Cancer stem cells are thought to be one of the driving forces behind distant metastasis, treatment resistance, and late-s...
Autores principales: | Doheny, Daniel, Sirkisoon, Sherona, Rimkus, Tadas, Zhu, Dongqin, Aguayo, Noah, Anguelov, Marlyn, Manore, Sara, Regua, Angelina, Thomas, Alexandra, Henson-Masters, Adrianna, Strowd, Roy, Lo, Hui-Wen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7401397/ http://dx.doi.org/10.1093/noajnl/vdaa073.042 |
Ejemplares similares
-
BSCI-14. tGLI1 is an actionable therapeutic target in breast cancer brain metastases
por: Doheny, Daniel, et al.
Publicado: (2021) -
BSCI-02. tGLI1 IS A NOVEL, ACTIONABLE TARGET FOR THE TREATMENT OF BREAST CANCER BRAIN METASTASES
por: Doheny, Daniel, et al.
Publicado: (2019) -
BSCI-13. TUMOR-SPECIFIC tGLI1 TRANSCRIPTION FACTOR MEDIATES BREAST CANCER BRAIN METASTASIS VIA ACTIVATING METASTASIS-INITIATING CANCER STEM CELLS AND ASTROCYTES IN THE TUMOR MICROENVIRONMENT
por: Sirkisoon, Sherona, et al.
Publicado: (2019) -
An FDA-Approved Antifungal, Ketoconazole, and Its Novel Derivative Suppress tGLI1-Mediated Breast Cancer Brain Metastasis by Inhibiting the DNA-Binding Activity of Brain Metastasis-Promoting Transcription Factor tGLI1
por: Doheny, Daniel, et al.
Publicado: (2022) -
Combined inhibition of JAK2-STAT3 and SMO-GLI1/tGLI1 pathways suppresses breast cancer stem cells, tumor growth, and metastasis
por: Doheny, Daniel, et al.
Publicado: (2020)